CN108291248B - 对atp结合位点进行突变的血管内皮抑制素突变体 - Google Patents

对atp结合位点进行突变的血管内皮抑制素突变体 Download PDF

Info

Publication number
CN108291248B
CN108291248B CN201280078261.4A CN201280078261A CN108291248B CN 108291248 B CN108291248 B CN 108291248B CN 201280078261 A CN201280078261 A CN 201280078261A CN 108291248 B CN108291248 B CN 108291248B
Authority
CN
China
Prior art keywords
mutant
activity
vascular endothelial
seq
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280078261.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108291248A (zh
Inventor
罗永章
刘鹏
鲁薪安
陈阳
付彦
常国栋
周代福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202410186085.0A priority Critical patent/CN117987505A/zh
Publication of CN108291248A publication Critical patent/CN108291248A/zh
Application granted granted Critical
Publication of CN108291248B publication Critical patent/CN108291248B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201280078261.4A 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体 Active CN108291248B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410186085.0A CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201110280441 2011-09-09
CN2011102804418 2011-09-09
CN201110280441.8 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410186085.0A Division CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (2)

Publication Number Publication Date
CN108291248A CN108291248A (zh) 2018-07-17
CN108291248B true CN108291248B (zh) 2024-03-08

Family

ID=47831548

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280078261.4A Active CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体
CN202410186085.0A Pending CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410186085.0A Pending CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Country Status (9)

Country Link
US (1) US10647968B2 (https=)
EP (1) EP2754718B1 (https=)
JP (1) JP6336389B2 (https=)
CN (2) CN108291248B (https=)
AU (1) AU2012306826B2 (https=)
CA (1) CA2848118C (https=)
IL (1) IL231419A0 (https=)
RU (1) RU2014113924A (https=)
WO (1) WO2013034116A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
EP3269731B1 (en) * 2015-02-13 2023-10-04 Tsinghua University Molecular design of recombinant protein drug
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
WO2018086603A1 (zh) * 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
EP3662922B1 (en) * 2017-07-30 2025-03-05 Tsinghua University A combination of endostatin and a dna double strand break inducing chemotherapeutic agent for treating p53(-) melanoma and p53(-) non-small cell lung cancer
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324818A (zh) * 2000-05-22 2001-12-05 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313251A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
EP2270055A4 (en) * 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324818A (zh) * 2000-05-22 2001-12-05 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
人血管内皮抑素诱导内皮细胞凋亡的机理研究;袁绍鹏;《中国博士学位论文全文数据库（电子期刊）》;20090815(第8期);第35页 *

Also Published As

Publication number Publication date
CN117987505A (zh) 2024-05-07
WO2013034116A1 (zh) 2013-03-14
US20150197733A9 (en) 2015-07-16
US10647968B2 (en) 2020-05-12
EP2754718A1 (en) 2014-07-16
AU2012306826A1 (en) 2014-04-03
JP2014531897A (ja) 2014-12-04
EP2754718B1 (en) 2017-12-13
RU2014113924A (ru) 2015-10-20
JP6336389B2 (ja) 2018-06-06
CA2848118A1 (en) 2013-03-14
CN108291248A (zh) 2018-07-17
HK1251864A1 (zh) 2019-04-26
IL231419A0 (en) 2014-04-30
AU2012306826B2 (en) 2018-01-04
US20140308263A1 (en) 2014-10-16
CA2848118C (en) 2023-09-05
EP2754718A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
CN108291248B (zh) 对atp结合位点进行突变的血管内皮抑制素突变体
CN100400657C (zh) 磷酸激酶及其应用
Capila et al. Annexin V–heparin oligosaccharide complex suggests heparan sulfate–mediated assembly on cell surfaces
JP3091769B2 (ja) プロテインキナーゼ
JP2021534776A (ja) リコンビナントタンパク質変異体
US6391574B1 (en) AFC1 and RCE1: isoprenylated CAAX processing enzymes
CN101875693A (zh) 具备抗血管生成活性的白蛋白变异体及其制备方法
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
CN114957491B (zh) 一种靶向结合β-catenin蛋白的多肽、多肽衍生物及其应用
Zhao et al. Earthworm fibrinolytic enzyme
Mercer et al. Na, K-ATPase Structure
HK1194771A (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
HK1194771B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
Heinrich et al. Neutron Reflectometry and Molecular Simulations Demonstrate HIV-1 Nef Homodimer Formation on Model Lipid Bilayers
HK1251864B (zh) 对atp结合位点进行突变的血管内皮抑制素突变体
CN111808938A (zh) Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
CN114848849B (zh) Pcsk9蛋白抑制剂在治疗心血管疾病中的应用
JP4232423B2 (ja) 新規ユビキチン特異プロテアーゼ
US20070020269A1 (en) Phosphokinase and the usage thereof
WO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤
CN102212126B (zh) 具有抑制内皮细胞生长活性的重组EDI-8t蛋白
CN119591675A (zh) 多肽、核酸、表达载体、药物组合物及其用途
CN115991789A (zh) 一种基于sh2超亲体的融合蛋白及应用
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
JP2005192567A (ja) チロシンキナーゼ遺伝子およびその遺伝子産物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251864

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant